Brief Report: Cancer Immunotherapy in Patients With Preexisting Rheumatic Disease: The Mayo Clinic Experience
出版年份 2018 全文链接
标题
Brief Report: Cancer Immunotherapy in Patients With Preexisting Rheumatic Disease: The Mayo Clinic Experience
作者
关键词
-
出版物
Arthritis & Rheumatology
Volume 70, Issue 3, Pages 356-360
出版商
Wiley
发表日期
2018-01-24
DOI
10.1002/art.40397
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity
- (2017) Ralf Gutzmer et al. EUROPEAN JOURNAL OF CANCER
- Inflammatory arthritis due to immune checkpoint inhibitors: challenges in diagnosis and treatment
- (2017) Laura C Cappelli et al. Immunotherapy
- Immune‐Related Adverse Events as a Biomarker in Non‐Melanoma Patients Treated with Programmed Cell Death 1 Inhibitors
- (2017) Julia Judd et al. ONCOLOGIST
- Opportunistic autoimmunity secondary to cancer immunotherapy (OASI): An emerging challenge
- (2017) M. Kostine et al. REVUE DE MEDECINE INTERNE
- Immune-Related Adverse Effects of Cancer Immunotherapy— Implications for Rheumatology
- (2017) Laura C. Cappelli et al. RHEUMATIC DISEASE CLINICS OF NORTH AMERICA
- The use of ipilimumab in patients with rheumatoid arthritis and metastatic melanoma
- (2016) B. Lee et al. ANNALS OF ONCOLOGY
- Immune-related adverse events with immune checkpoint blockade: a comprehensive review
- (2016) J.M. Michot et al. EUROPEAN JOURNAL OF CANCER
- Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial
- (2016) F Stephen Hodi et al. LANCET ONCOLOGY
- Immune checkpoints and rheumatic diseases: what can cancer immunotherapy teach us?
- (2016) Michiel van der Vlist et al. Nature Reviews Rheumatology
- Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab
- (2016) J. Weber et al. Cancer Immunology Research
- Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
- (2016) Douglas B. Johnson et al. JAMA Oncology
- Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes
- (2015) M. Freeman-Keller et al. CLINICAL CANCER RESEARCH
- Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma
- (2015) Ahmad A. Tarhini et al. Journal for ImmunoTherapy of Cancer
- Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab
- (2013) Jeffrey S. Weber et al. CANCER
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search